ZOU Yang, LIU Yuan, HUANG Wei, CUI Jing-rong, JIN Hong-wei, ZHANG Liang-ren, LIU Zhen-ming. Advances on anti-neoplastic STAT3 inhibitorsJ. Acta Pharmaceutica Sinica, 2018,53(10): 1598-1608. doi: 10.16438/j.0513-4870.2018-0559
Citation: ZOU Yang, LIU Yuan, HUANG Wei, CUI Jing-rong, JIN Hong-wei, ZHANG Liang-ren, LIU Zhen-ming. Advances on anti-neoplastic STAT3 inhibitorsJ. Acta Pharmaceutica Sinica, 2018,53(10): 1598-1608. doi: 10.16438/j.0513-4870.2018-0559

Advances on anti-neoplastic STAT3 inhibitors

  • Signal transducer and activator of transcription 3 (STAT3) is a kind of signal transduction protein involved in cell proliferation, differentiation, apoptosis and other important physiological processes in response to a large number of cytokines and growth factors in cells. It has been shown that constitutive activation of STAT3 is closely associated with oncogenesis and tumorigenesis. Inhibition of aberrant STAT3 signaling has been one of promising strategies for the development of anti-neoplastic therapeutics. The review summarizes the latest progress of STAT3 inhibitors in recent years from the perspective of targeting N-terminal domain, DNA binding domain, SH2 domain and C-terminal transactivation domain of STAT3.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return